Skip to main content
. 2026 Feb 28;32(4):1249–1256. doi: 10.1038/s41591-026-04263-3

Table 2.

TRAEs occurring in ≥10% of patients and grade ≥3 TRAEs in more than one patient

Preferred term 30 mg (N = 17) n (%) 50 mg (N = 20) n (%) 70 mg (N = 13) n (%) 100 mg (N = 6) n (%) Total (N = 56) n (%)
TRAE ≥10% Grade ≥3 TRAE TRAE ≥10% Grade ≥3 TRAE TRAE ≥10% Grade ≥3 TRAE TRAE ≥10% Grade ≥3 TRAE TRAE ≥10% Grade ≥3 TRAE
At least one event 16 (94.1) 6 (35.3) 19 (95.0) 12 (60.0) 12 (92.3) 10 (76.9) 6 (100) 5 (83.3) 53 (94.6) 33 (58.9)
Platelet count decreased* 8 (47.1) 2 (11.8) 10 (50.0) 4 (20.0) 11 (84.6) 5 (38.5) 3 (50.0) 1 (16.7) 32 (57.1) 12 (21.4)
Fatigue* 7 (41.2) 10 (50.0) 4 (20.0) 6 (46.2) 1 (7.7) 4 (66.7) 1 (16.7) 27 (48.2) 6 (10.7)
Anemia 5 (29.4) 4 (23.5) 5 (20.0) 3 (15.0) 5 (38.5) 5 (38.5) 4 (66.7) 3 (50.0) 19 (33.9) 15 (26.8)
Hyperglycemia* 2 (11.8) 6 (30.0) 2 (10.0) 6 (46.2) 1 (7.7) 2 (33.3) 1 (16.7) 16 (28.6) 4 (7.1)
AST increased 3 (17.6) 2 (10.0) 6 (46.2) 2 (33.3) 13 (23.2)
Hypertriglyceridemia 4 (23.5) 5 (25.0) 2 (15.4) 2 (33.3) 13 (23.2)
Diarrhea 2 (11.8) 3 (15.0) 3 (23.1) 4 (66.7) 12 (21.4)
ALT increased 1 (5.9) 2 (10.0) 6 (46.2) 2 (33.3) 11 (19.6)
Decreased appetite 3 (17.6) 4 (20.0) 3 (23.1) 1 (16.7) 11 (19.6)
Dry eye 5 (29.4) 2 (10.0) 2 (15.4) 2 (33.3) 11 (19.6)
Nausea 2 (11.8) 2 (10.0) 2 (15.4) 2 (33.3) 8 (14.3)
Hypomagnesemia 2 (11.8) 2 (10.0) 2 (15.4) 1 (16.7) 7 (12.5)
Hypophosphatemia 3 (17.6) 3 (15.0) 0 1 (16.7) 7 (12.5)
Vomiting 2 (11.8) 3 (15.0) 1 (7.7) 1 (16.7) 7 (12.5)
GGT increased 1 (5.9) 0 3 (23.1) 2 (33.3) 6 (10.7)
Hypokalemia 1 (5.9) 2 (10.0) 0 3 (50.0) 6 (10.7)

*The following combined terms are included in this presentation: platelet count decreased includes thrombocytopenia; fatigue includes malaise and asthenia; hyperglycemia includes diabetes

AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase.